*From the Institute of Health Economics; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta; and †Health Utilities Inc., Dundas, Ontario.
‡From Innovus Research Inc., Burlington, Ontario.
§From the Centre for the Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario.
¶From the Prudential Insurance Company of America, Newark, New Jersey.
From the ∥Centre for Health Economics and Policy Analysis; #Department of Clinical Epidemiology and Biostatistics; the **Centre for Minimal Access Surgery, Department of Surgery; the ††Office of Gerontological Studies and Department of Sociology; and the ‡‡Department of Psychiatry, McMaster University McMaster University, Hamilton, Ontario.
Support from Ontario (Canada) Ministry of Health grant #04020; Natural Science and Engineering Research Council grant #10020; grants from Astra Pharma Inc., Bayer Inc. Boehringer-Ingelheim, Bristol-Myers Squibb, Burroughs Wellcome Inc., Eli Lilly, Glaxo Canada Inc., Janssen Pharmaceutica Research Foundation, Nordic Merrell Dow Research, Ortho-McNeil and CILAG, Pharmaceutical Manufacturers Association of Canada (Health Economics Committee), and Sandoz Canada Inc. are gratefully acknowledged. The funding sources played no role in the design, interpretation, or analysis of the project and have not reviewed or approved of this manuscript. Salary support for David Feeny is provided by an award from the Canadian Institutes of Health Research/Rx & D Program.
An earlier version of the paper was presented at the 4th Annual Conference of the International Society for Quality of Life Research, Vienna, November 5 to 9, 1997.
Address correspondence and reprint requests to: David Feeny, Institute of Health Economics, #1200, 10405 Jasper Ave, Edmonton, AB T5J 3N4 Canada. E-mail: [email protected]
Received July 24, 2001; initial review September 29, 2001; accepted October 1, 2001.
(Med Care 2002;40:113-128)
